Ipsen Expands Exelixis Collaboration For Cabometyx In Advanced Neuroendocrine Tumors
- Stock Market Stocks to buy Stocks to sell
admin
- 0
- 1 minute read
(RTTNews) – Ipsen (IPSEY) announced confirmation of an expanded collaboration and license agreement with Exelixis for the development of Cabometyx (cabozantinib) in advanced pancreatic neuroendocrine tumors or pNETs and advanced extra-pancreatic neuroendocrine tumors or epNETs.
:max_bytes(150000):strip_icc():format(jpeg)/FlyFirstClassforCheap-d3852e14d3984fddb9a46fcb17fc93c2.jpg "How to Fly First Class for Cheap")
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-506997606-3aeda39d7c734e459725400f855c816d.jpg "Is Shopping at Big-Box Stores Worth It? Factors to Consider")
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-1169041231-5052d200552d467baab33417938984a3.jpg "10 Low-Risk Income Sources for a Safer Retirement")
